Statement of Changes in Beneficial Ownership (4)
March 01 2016 - 4:19PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Shea Thomas A.
|
2. Issuer Name
and
Ticker or Trading Symbol
EPIRUS Biopharmaceuticals, Inc.
[
EPRS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Financial Officer
|
(Last)
(First)
(Middle)
C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/27/2016
|
(Street)
BOSTON, MA 02116
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
2/27/2016
|
|
M
|
|
1044
|
A
|
(1)
|
29970
|
D
|
|
Common Stock
|
2/27/2016
|
|
M
|
|
3073
|
A
|
(2)
|
33043
|
D
|
|
Common Stock
|
2/27/2016
|
|
F
(3)
|
|
1554
|
D
|
$2.80
(4)
|
31489
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Restricted Stock Units
|
(1)
|
2/27/2016
|
|
M
|
|
|
1044
|
(1)
|
(1)
|
Common Stock
|
1044
|
$0.00
|
0
|
D
|
|
Restricted Stock Units
|
(2)
|
2/27/2016
|
|
M
|
|
|
3073
|
(2)
|
(2)
|
Common Stock
|
3073
|
$0.00
|
9217
|
D
|
|
Explanation of Responses:
|
(
1)
|
Each Restricted Stock Unit ("RSU") represented a contingent right to receive a share of the Issuer's common stock, vested in full on February 27, 2016, and had no expiration date.
|
(
2)
|
Each RSU represents a contingent right to receive a share of the Issuer's common stock, vests in four (4) substantially equal annual installments beginning on February 27, 2016 provided the Reporting Person remains continuously employed by the Issuer through each vesting date, and has no expiration date.
|
(
3)
|
Represents shares of the Issuer's common stock withheld by the Issuer to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portions of the RSUs as reflected in this Form 4.
|
(
4)
|
Represents the closing price of shares of the Issuer's common stock on the business day prior to the vesting date for such RSUs.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Shea Thomas A.
C/O EPIRUS BIOPHARMACEUTICALS, INC.
699 BOYLSTON STREET, 8TH FLOOR
BOSTON, MA 02116
|
|
|
Chief Financial Officer
|
|
Signatures
|
/s/ Marina Breed, Attorney-in-Fact
|
|
3/1/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Historical Stock Chart
From Apr 2024 to May 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Historical Stock Chart
From May 2023 to May 2024